Advanced Microbiome Therapeutics Accelerate MASLD Recovery by Restoring Intestinal Microbiota Equilibrium and the Gut-Liver Axis in a Mouse Model
Artikel i vetenskaplig tidskrift, 2025
Gut microbiota dysbiosis and endocrine dysregulation are key players in metabolic dysfunction-associated steatotic liver disease (MASLD) development. This study evaluated whether advanced microbiome therapeutics can restore intestinal microbial equilibrium and gut-liver axis balance during MASLD recovery. MASLD was induced in mice using a high-fat, high-sugar diet, and then shifted to a standard diet, where intervention groups received engineered Escherichia coli Nissle 1917 expressing IGF1 (EcNI) or aldafermin (EcNA), and control groups received E. coli Nissle 1917 vehicle (EcN) or no microbial intervention (CTRL). EcNI and EcNA improved MASLD recovery compared to controls by lowering hepatic fat, plasma cholesterol, and body weight, while increasing bacterial diversity, plasma acetate, and propionate, and modulating particular microbial groups, potentially alleviating dysbiosis. Additionally, EcNI and EcNA downregulated acetyl-CoA, the steroid hormone biosynthesis pathway, and EcNA upregulated the pentose phosphate pathway and pyruvate, which are related to oxidative stress reduction. These results suggest that EcNI and EcNA are potential novel treatments for MASLD.
insulin-like growth factor 1
aldafermin
nonalcoholic fatty liver disease (NAFLD)
integrative multiomics
E. coli Nissle 1917
fibroblast growth factor 19
Författare
Johnson Lok
Itä-Suomen Yliopisto
Congjia Chen
The University of Hong Kong
Valeria Iannone
Itä-Suomen Yliopisto
Ambrin Farizah Babu
Afekta Technologies
Itä-Suomen Yliopisto
Emily Kwun Kwan Lo
The University of Hong Kong
Ruben Vazquez-Uribe
Flanders Interuniversity Institute for Biotechnology
Novo Nordisk Fonden
Troels Holger Vaaben
Novo Nordisk Fonden
Mikko Kettunen
Itä-Suomen Yliopisto
Otto Savolainen
Chalmers, Life sciences, Infrastrukturer
Itä-Suomen Yliopisto
Ursula Schwab
Itä-Suomen Yliopisto
Kuopio University Hospital
Morten Otto Alexander Sommer
Novo Nordisk Fonden
K. Hanhineva
Turun Yliopisto
Afekta Technologies
Itä-Suomen Yliopisto
M. Kolehmainen
Itä-Suomen Yliopisto
Hani El-Nezami
Itä-Suomen Yliopisto
The University of Hong Kong
Carlos Gómez-Gallego
Itä-Suomen Yliopisto
Journal of Agricultural and Food Chemistry
0021-8561 (ISSN) 1520-5118 (eISSN)
Vol. 73 24 15199-15214Ämneskategorier (SSIF 2025)
Medicinska biovetenskaper
DOI
10.1021/acs.jafc.5c01674